Speakers: Oliver Philps, PhD, medicinal chemist; Scott Morano, Ipsos; Roberto Cortese, Ipsos
Organizers: Shichang Miao, PBSS; Dean Wilson, PBSS
Date: 2024-08-22
Time: 11:30-14:30 Pacific Time
Registration fee: 0
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2024-08-21  (it will close sooner if the seating cap is reached)

About the Topic

Glucagon-like peptide-1 (GLP-1) receptor agonists have recently received significant media coverage for their compelling efficacy in several indications. While most of the recent fanfare has been related to their role in weight loss, GLP-1 receptor agonists have been a mainstay of the type 2 diabetes treatment landscape for the past 2 decades. GLP-1 receptor agonists have also recently shown efficacy in reducing heart disease risk and treating certain chronic kidney diseases, which has opened the door to potential new indications and label expansions for this drug class. This symposium will explore the evolution of these and other agents (e.g. gastric inhibitory polypeptide [GIP] receptor agonists), including clinical efficacy and safety results, HCP and consumer perspectives, market adoption, and the access, reimbursement, and intellectual property (IP) landscapes. Speakers will include experts in drug discovery and development, and market research.

Symposium topics 

• Diabetes / obesity and treatments
• GLP-1 receptor agonists for diabetes and obesity: evolution and current marketed therapies, clinical efficacy and safety
• GIP receptor agonists and dual GLP-1/GIP receptor agonists
• Market landscape: revenues, HCP perspectives, consumer viewpoints, access and reimbursement
• GLP-1 in other indications: CV, kidney disease, MASH
• On the horizon: the obesity clinical pipeline, IP landscape, and the potential arrival of generics